Physician profile
Deborah Reed
NPI 1891808135
$394,222.30
in general payments reported to CMS, 2019-2025
33 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112K · 2020: $77K · 2021: $77K · 2022: $60K · 2023: $28K · 2024: $18K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Consulting Fee: $15K · Honoraria: $8,663 · Food and Beverage: $6,316 · Travel and Lodging: $3,135 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,949.25 |
| Consulting Fee | $14,605.71 |
| Honoraria | $8,662.50 |
| Food and Beverage | $6,315.58 |
| Travel and Lodging | $3,135.41 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $109,498.75 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Amgen INC. | $64,249.74 | 2019-2024 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $53,500.26 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $53,144.13 | 2021-2025 | |
| Lundbeck LLC | $28,138.35 | 2020-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $21,334.85 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19,556.88 | 2022 | |
| Impel Pharmaceuticals INC. | $12,768.41 | 2022-2023 | Trudhesa |
| Allergan, INC. | $11,301.43 | 2019-2021 | |
| Pfizer INC. | $3,861.09 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $3,218.85 | 2019-2021 | |
| Axsome Therapeutics, INC. | $2,888.85 | 2025 | Symbravo |
| Biodelivery Sciences International, INC. | $2,500.00 | 2021 | |
| Tonix Medicines, INC. | $2,398.84 | 2023-2025 | Zembrace Symtouch |
| Bausch Health US, LLC | $2,068.78 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $2,052.00 | 2023-2024 | Ztlido |
| Supernus Pharmaceuticals, INC. | $557.64 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $338.69 | 2020-2023 | |
| Amneal Pharmaceuticals LLC | $236.11 | 2020-2025 | Brekiya |
| Impel Pharmaceuticals LLC | $121.81 | 2024-2025 | Trudhesa |
| Arbor Pharmaceuticals, INC. | $103.17 | 2021 | |
| Currax Pharmaceuticals LLC | $81.50 | 2021-2024 | Onzetra Xsail |
| Assertio Therapeutics, INC. | $60.44 | 2019-2020 | |
| Almatica Pharma LLC | $49.45 | 2021 | |
| Collegium Pharmaceutical, INC. | $48.93 | 2022 | |
| Zyla Life Sciences, INC. | $34.41 | 2019 | |
| Merz North America, INC. | $32.72 | 2019 | |
| Tersera Therapeutics LLC | $26.16 | 2019 | |
| Averitas Pharma INC. | $24.86 | 2024 | Qutenza |
| Merz Pharmaceuticals, LLC | $13.72 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.48 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.